Therapy of inflammatory bowel disease

Gastroenterology

Volumn 118, Issue 2 SUPPL., 2000, Pages

  Sands, Bruce E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; HEPARIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NICOTINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBIOTIC THERAPY; BIOTECHNOLOGY; BLOOD TOXICITY; CARDIOTOXICITY; CROHN DISEASE; DRUG CHOICE; DRUG FORMULATION; ENTERITIS; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TOXICITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

EID: 0033981670     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(00)70007-2     Document Type: Article

References (144)

1. DK. Podolsky Inflammatory bowel disease (1) N Engl J Med 325 1991 928 937
2. JD Taurog JA Richardson JT Croft WA Simmons M Zhou JL Fernandez-Sueiro E Balish RE. Hammer The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats J Exp Med 180 1994 2359 2364
3. B Sadlack H Merz H Schorle A Schimpl AC Feller I. Horak Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene Cell 75 1993 253 261
4. MF Kagnoff L. Eckmann Epithelial cells as sensors for microbial infection J Clin Invest 100 1997 6 10
5. L Mayer D Eisenhardt P Salomon W Bauer R Plous L. Piccinini Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease Gastroenterology 100 1991 3 12
6. L Chan L. Mayer Antigen priming, not tolerance, with oral antigen administration in inflammatory bowel disease Gastroenterology 110 1996 A881 (abstr)
7. DJ Lenschow GHT Su LA Zuckerman N Nabavi CL Jellis GS Gray J Miller JA. Bluestone Expression and functional significance of an additional ligand for CTLA-4 Proc Natl Acad Sci USA 90 1993 11054 11058
8. CA Janeway K. Bottomly Signals and signs for lymphocyte responses Cell 76 1994 275 285
9. VA Boussiotis GJ Freeman JG Gribben J Daley G Gray LM. Nadler Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation Proc Natl Acad Sci USA 90 1993 11059 11063
10. E Stüber W Strober M. Neurath Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion J Exp Med 183 1996 693 698
11. M De Carli MM D’Elios G Zancuoghi S Romagnani G. Del Prete Human Th1 and Th2 cells: functional properties, regulation of development and role in autoimmunity Autoimmunity 18 1994 301 308
12. RB. Sartor Review article: how relevant to human inflammatory bowel disease are current animal models of intestinal inflammation? Aliment Pharmacol Ther 11 1997 89 96 discussion 96–97
13. SE Plevy CJ Landers J Prehn NM Carramanzana RL Deem D Shealy A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease J Immunol 159 1997 6276 6282
14. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5 J Immunol 157 1996 1261 1270
15. P Desreumaux E Brandt L Gambiez D Emilie K Geboes O Klein N Ectors A Cortot M Capron JF. Colombel Distinct cytokine patterns in early and chronic ileal lesions of Crohn’s disease Gastroenterology 113 1997 118 126
16. CA Wenner ML Guler SE Macatonia A O’Garra KM. Murphy Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development J Immunol 156 1996 1442 1447
17. TT Pizarro MH Michie M Bentz J Woraratanadharm MF Smith Jr E Foley CA Moskalukca SJ Bickston F. Cominelli IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells J Immunol 162 1999 6829 6835
18. CA. Dinarello IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family J Allergy Clin Immunol 103 1999 11 24
19. WD Creery F Diaz-Mitoma L Filion A. Kumar Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype Eur J Immunol 26 1996 1273 1277
20. DF Fiorentino MW Bond TR. Mosmann Two types of mouse T helper cell. IV. TH2 clones secrete a factor that inhibits cytokine production by TH1 clones J Exp Med 170 1989 2081 2095
21. S Schreiber A Raedler WF Stenson RP. MacDermott The role of the mucosal immune system in inflammatory bowel disease Gastroenterol Clin North Am 21 1992 451 502
22. B. Beutler TNF, immunity and inflammatory disease: lessons of the past decade J Invest Med 43 1995 227 235
23. TT MacDonald SLF. Pender Proteolytic enzymes in inflammatory bowel disease Inflamm Bowel Dis 4 1998 157 164
24. TA. Springer Traffic signals for lymphocyte recirculation and leukocyte emigration Cell 76 1994 301 314
25. DK Podolsky R Lobb N King CD Benjamin B Pepinsky P Sehgal M. de Beaumont Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody J Clin Invest 92 1993 372 380
26. + T cells J Immunol 158 1997 2099 2106
27. M Reinshagen B Egger F Procaccino VE. Eysselein Neuropeptides in inflammatory bowel disease: an update Inflamm Bowel Dis 3 1997 303 313
28. R Modigliani JY Mary JF Simon A Cortot JC Soule JP Gendre E. Rene Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives Gastroenterology 98 1990 811 818
29. MB. Grisham Oxidants and free radicals in inflammatory bowel disease Lancet 344 1994 859 861
30. L Molin O. Stendahl The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis Acta Medica Scand 206 1979 451 457
31. 4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid Aliment Pharmacol Ther 2 1988 203 211
32. GC Burress MW Musch DA Jurivich J Welk EB. Chang Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells Gastroenterology 113 1997 1474 1479
33. CP Willoughby RE Cowan SR Gould RJ Machell JB. Stewart Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis Scand J Gastroenterol Suppl 148 1988 40 44
34. MC Rijk RA van Hogezand HJ van Lier JH. van Tongeren Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial Ann Intern Med 114 1991 445 450
35. SA Riley V Mani MJ Goodman ME Herd S Dutt LA. Turnberg Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse Gut 29 1988 669 674
36. SA Riley V Mani MJ Goodman ME Herd S Dutt LA. Turnberg Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis Gastroenterology 94 1988 1383 1389
37. D. Rachmilewitz Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial BMJ 298 1989 82 86
38. A Andreoli S Spinella S Levenstein C. Prantera 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis Ital J Gastroenterol 26 1994 121 125
39. H Malchow K Ewe JW Brandes H Goebell H Ehms H Sommer H. Jesdinsky European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment Gastroenterology 86 1984 249 266
40. RW Summers DM Switz JT Sessions Jr JM Becktel WR Best F Kern Jr JW. Singleton National Cooperative Crohn’s Disease Study: results of drug treatment Gastroenterology 77 1979 847 869
41. JW Singleton SB Hanauer GL Gitnick MA Peppercorn MG Robinson LD Wruble EL Krawitt Pentasa Crohn’s Disease Study Group Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial Gastroenterology 104 1993 1293 1301
42. WJ Tremaine KW Schroeder JM Harrison AR. Zinsmeister A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis J Clin Gastroenterol 19 1994 278 282
43. F Martin LR Sutherland IT Beck AH Anderson CN Williams F Saibil J Barrowman S. Lemire Oral 5-ASA versus prednisone in short term treatment of Crohn’s disease: a multicentre controlled trial Can J Gastroenterol 4 1990 452 457
44. K Maier HJ Frick U von Gaisberg T Tuefel U. Klotz Clinical efficacy of oral mesalazine in Crohn’s disease Can J Gastroenterol 4 1990 13 18
45. C Camma M Giunta M Rosselli M. Cottone Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables Gastroenterology 113 1997 1465 1473
46. AA Moss JV Carbone HY. Kressel Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn’s disease AJR Am J Roentgenol 131 1978 787 790
47. S Rockwell CG Irvin MH. Neaderland Inhibition of delayed hypersensitivity by metronidazole and misonidazole Int J Radiat Oncol Biol Phys 9 1983 701 706
48. T Yoshimura C Kurita E Usami T Nakao S Watanabe J Kobayashi F Yamazaki H. Nagai Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells Chemotherapy 42 1996 459 464
49. L Sutherland J Singleton J Sessions S Hanauer E Krawitt G Rankin R Summers H Mekhijran N Greenberger M Kelly J Levine A Thomson E. Alpert Double blind, placebo controlled trial of metronidazole in Crohn’s disease Gut 32 1991 1071 1075
50. B Ursing T Alm F Barany I Bergelin K Ganrot-Norlin J Hoevels E Prokipchuk B Huitfeldt G Jamerot V Krause A Krook B Lindstrom O Nordle A. Rosen A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. II. Result Gastroenterology 83 1982 550 562
51. J Jakobovits MM. Schuster Metronidazole therapy for Crohn’s disease and associated fistulae Am J Gastroenterol 79 1984 533 540
52. P Rutgeerts M Hiele K Geboes M Peeters F Penninckx R Aerts R. Kerremans Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection Gastroenterology 108 1995 1617 1621
53. C Prantera E Berto ML Scribano G. Falasco Use of antibiotics in the treatment of active Crohn’s disease: experience with metronidazole and ciprofloxacin Ital J Gastroenterol 30 1998 602 606
54. JF Colombel M Lemann M Cassagnou Y Bouhnik B Duclos JL Dupas B Notteghem JY. Mary A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) Am J Gastroenterol 94 1999 674 678
55. SL Greenbloom AH Steinhart GR. Greenberg Combination ciprofloxacin and metronidazole for active Crohn’s disease Can J Gastroenterol 12 1998 53 56
56. UM Turunen MA Farkkila K Hakala K Seppala A Sivonen M Ogren M Vuoristo VV Valtonen TA. Miettinen Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study Gastroenterology 115 1998 1072 1078
57. G Jarnerot P Rolny H. Sandberg-Gertzen Intensive intravenous treatment of ulcerative colitis Gastroenterology 89 1985 1005 1013
58. SC Truelove LJ. Witts Cortisone in ulcerative colitis. Final report on a therapeutic trial BMJ 2 1955 1041 1048
59. A Angeli RG Masera ML Sartori N Fortunati S Racca A Dovio A Staurenghi R. Frairia Modulation by cytokines of glucocorticoid action Ann NY Acad Sci 876 1999 210 220
60. PJ. Barnes Nuclear factor-kappa B Int J Biochem Cell Biol 29 1997 867 870
61. NJ Goulding HS Euzger SK Butt M. Perretti Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation Inflamm Res 47 1998 S158 S165
62. M. Goppelt-Struebe Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids Biochem Pharmacol 53 1997 1389 1395
63. P Munkholm E Langholz M Davidsen V. Binder Frequency of glucocorticoid resistance and dependency in Crohn’s disease Gut 35 1994 360 362
64. R. Lofberg New steroids for inflammatory bowel disease Inflamm Bowel Dis 1 1995 135 141
65. DJ Crawford JL Maddocks DN Jones P. Szawlowski Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects J Med Chem 39 1996 2690 2695
66. DH Present BI Korelitz N Wisch JL Glass DB Sachar BS. Pasternak Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study N Engl J Med 302 1980 981 987
67. DC Pearson GR May GH Fick LR. Sutherland Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis Ann Intern Med 123 1995 132 142
68. WJ Sandborn WJ Tremaine DC Wolf SR Targan CA Sninsky LR Sutherland SB Hanauer JW McDonald BG Feagan RN Fedorak KL Isaacs MG Pike DC Mays JJ Lipsky S Gordon CS Kleoudis RH. Murdock Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. North American Azathioprine Study Group Gastroenterology 117 1999 527 535
69. MC Dubinsky S Lamothe HY Yang S Targan D Sinnett Y Theoret E. Seidman Optimizing and individualizing 6-MP therapy in IBD: the role of 6-MP metabolite levels and TPMT genotyping Gastroenterology 116 1999 A702 (abstr)
70. M. Seitz Molecular and cellular effects of methotrexate Curr Opin Rheumatol 11 1999 226 232
71. BG Feagan J Rochon RN Fedorak EJ Irvine G Wild L Sutherland AH Steinhart GR Greenberg R Gillies M. Hopkins Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators N Engl J Med 332 1995 292 297
72. R Oren M Moshkowitz S Odes S Becker D Keter I Pomeranz C Shirin I Reisfeld E Broide A Lavy A Fich R Eliakim J Patz Y Villa N Arber T. Gilat Methotrexate in chronic active Crohn’s disease: a double-blind, randomized, Israeli multicenter trial Am J Gastroenterol 92 1997 2203 2209
73. DA Gerber CA Bonham AW. Thomson Immunosuppresive agents: recent developments in molecular action and clinical application Transplant Proc 30 1998 1573 1579
74. J Brynskov L Freund SN Rasmussen K Lauritsen OS de Muckadell N Williams AS MacDonald R Tanton F Molina MC Campanini P Bianchi T Ranzi F Quarto di Palo A Malchow-Møller OO Thomsen U Tage-Jensen V Binder P. Riis A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease N Engl J Med 321 1989 845 850
75. BG Feagan JW McDonald J Rochon A Laupacis RN Fedorak D Kinnear F Saibil A Groll A Archambault R Gillies B Valberg EJ Irvine Canadian Crohn’s Relapse Prevention Trial Investigators Low-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators N Engl J Med 330 1994 1846 1851
76. SB Hanauer MB. Smith Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A Am J Gastroenterol 88 1993 646 649 [see comments]
77. S Lichtiger DH Present A Kornbluth I Gelernt J Bauer G Galler F Michelassi S. Hanauer Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841 1845
78. A Kornbluth DH Present S Lichtiger S. Hanauer Cyclosporin for severe ulcerative colitis: a user’s guide Am J Gastroenterol 92 1997 1424 1428
79. F Fernandez-Banares X Bertran M Esteve-Comas E Cabre M Menacho P Humbert R Planas MA. Gassull Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis Am J Gastroenterol 91 1996 2498 2499
80. WJ Sandborn WJ Tremaine KW Schroeder KP Batts GM Lawson BL Steiner JM Harrison AR. Zinsmeister A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis Gastroenterology 106 1994 1429 1435
81. K Oppong CO. Record Neoral may be as effective as intravenous cyclosporine in the treatment of steroid-resistant ulcerative colitis Am J Gastroenterol 93 1998 1188 1189
82. SA Siegel DJ Shealy MT Nakada J Le DS Woulfe L Probert G Kollias J Ghrayeb J Vilcek PE. Daddona The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo Cytokine 7 1995 251 259
83. BJ Scallon MA Moore H Trinh DM Knight J. Ghrayeb Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 1995 251 259
84. HM van Dullemen SJ van Deventer DW Hommes HA Bijl J Jansen GN Tytgat J. Woody Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109 1995 129 135
85. RP McCabe J Woody S van Deventer SR Targan L Mayer R van Hogezand P Rutgeerts SB Hanauer DK Podolsky CO. Elson A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease Gastroenterology 110 1996 A962 (abstr)
86. SR Targan SB Hanauer SJH van Deventer L Mayer DH Present T Braakman KL DeWoody TF Schaible PJ. Rutgeerts A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease N Engl J Med 337 1997 1029 1035
87. P Rutgeerts G D’Haens S Targan E Vasiliauskas SB Hanauer DH Present L Mayer RA van Hogezand T Braakman KL DeWoody TF Schaible SJH. van Deventer Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease Gastroenterology 117 1999 761 769
88. DH Present P Rutgeerts S Targan SB Hanauer L Mayer RA van Hogezand DK Podolsky BE Sands T Braakman KL DeWoody TF Schaible SJ. van Deventer Infliximab for the treatment of fistulas in patients with Crohn’s disease N Engl J Med 340 1999 1398 1405
89. SB Hanauer PJ Rutgeerts G D’Haens SR Targan L Kam DH Present L Mayer C Wagner J Lasorda B Sands RA. Livingston Delayed hypersensitivity to infliximab (remicade) re-infusion after 2–4 year interval without treatment Gastroenterology 116 1999 A731
90. TF Schaible T Braakman P Marsters G. Harriman Long-term safety of infliximab (anti-TNFa antibody) in patients with rheumatoid arthritis: results of the ATTRACT trial Gastroenterology 116 1999 A813 (abstr)
91. SJ Bickston GR Lichtenstein KO Arseneau RB Cohen F. Cominelli The relationship between infliximab treatment and lymphoma in Crohn’s disease Gastroenterology 117 1999 1433 1437
92. WA Stack SD Mann AJ Roy P Heath M Sopwith J Freeman G Holmes R Long A Forbes MA. Kamm Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease Lancet 349 1997 521 524
93. R de Waal Malefyt J Haanen H Spits MG Roncarolo A te Velde C Figdor K Johnson R Kastetein H Yssel JE. deVries Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression J Exp Med 174 1991 915 924
94. L Ding EM. Shevach IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function J Immunol 148 1992 3133 3139
95. L Ding PS Linsley LY Huang RN Germain EM. Shevach IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression J Immunol 151 1993 1224 1234
96. DF Fiorentino A Zlotnik P Vieira TR Mosmann M Howard KW Moore A. O’Garra IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells J Immunol 146 1991 3444 3451
97. D Rennick N Davidson D. Berg Interleukin-10 gene knock-out mice: a model of chronic inflammation Clin Immunol Immunopathol 76 1995 S174 S178
98. SJ van Deventer CO Elson RN Fedorak Crohn’s Disease Study Group Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease Gastroenterology 113 1997 383 389
99. RN Fedorak A Gangl CO Elson P Rutgeerts S Schreiber G Wild S Hanauer SJH van Deventer P. Grint Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn’s disease (STEMM-CD) Gastroenterology 114 1998 A974 (abstr)
100. S Schreiber RN Fedorak OH Nielsen G Wild NC Williams M Jacyna BA Lashner M Cohard A Kilian A Lebeaut SB. Hanauer A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn’s disease (CACD) Gastroenterology 114 1998 A1080 (abstr)
101. S Schreiber RN Fedorak G Wild A Gangl S Targan M Jacyna JP Wright A Kilian M Cohard A Lebeaut WJ. Tremaine Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis Gastroenterology 114 1998 A1080 (abstr)
102. MS Gordon WJ McCaskill-Stevens LA Battiato J Loewy D Loesch E Breeden R Hoffman KJ Beach B Kuca J Kaye GW. Sledge A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy Blood 87 1996 3615 3624
103. CS. Potten Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time Stem Cells 14 1996 452 459
104. BS Qiu CJ Pfeiffer JC Keith Jr. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats Dig Dis Sci 41 1996 1625 1630
105. JC Keith Jr LM Albert TJ Ferranti JE Erickson LE Mason LH Donnelly BR Misra RB. Schaub Recombinant human interleukin-11 (rhIL-11) decreases inflammatory bowel disease in HLA-B27 transgenic rats Gastroenterology 108 1995 A846 (abstr)
106. JC Keith Jr L Albert RG. Schaub rhIL-11 decreases the severity of acetic acid-induced colonic injury in rats Gastroenterology 106 1994 A708 (abstr)
107. BE Sands S Bank CA Sninsky M Robinson S Katz JW Singleton PB Miner MA Safdi S Galandiuk SB Hanauer GW Varilek AL Buchman VD Rodgers B Salzberg B Cai J Loewy MF DeBruin H Rogge M Shapiro US. Schwertschlag Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s disease Gastroenterology 117 1999 58 64
108. BE Sands B Winston B Salzberg C Barish M Safdi L Wruble G Varilek J Singleton S Katz PB Miner M Shapiro US. Schwertzschlag A randomized, double-masked, placebo-controlled study of recombinant human interleukin eleven (rhIL-11) in Crohn’s disease subjects not receiving prednisone Gastroenterology 116 1999 A811 (abstr)
109. BR Yacyshyn MB Bowen-Yacyshyn L Jewell JA Tami CF Bennett DL Kisner WR. Shanahan A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease Gastroenterology 114 1998 1133 1142
110. FH Gordon CWY Lai MI Hamilton MC Allison M Fouweather S Donoghue C Greenlees PL Amlot ED Srivastava J Subhani RE. Pounder Randomised double-blind placebo-controlled trial of recombinant humanised antibody to a4 integrin (antegren) in active Crohn’s disease Gastroenterology 116 1999 A726 (abstr)
111. FH Gordon MI Hamilton S Donoghue PL Amlot C Greenlees D Rowley-Jones RE. Pounder Treatment of active ulcerative colitis with a recombinant humanised antibody to a4 integrin (antegren) Gastroenterology 116 1999 A726 (abstr)
112. W Kruis E Schutz P Fric B Fixa G Judmaier M. Stolte Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis Aliment Pharmacol Ther 11 1997 853 858
113. HA. Malchow Crohn’s disease and Escherichia coli .. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 25 1997 653 658
114. BJ Rembacken AM Snelling PM Hawkey DM Chalmers ATR. Axon Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial Lancet 354 1999 635 639
115. WJ. Sandborn Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease Am J Gastroenterol 92 1997 876 879
116. K Fellermann D Ludwig M Stahl T David-Walek EF. Stange Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506) Am J Gastroenterol 93 1998 1860 1866
117. A Bousvaros A Wang AM. Leichtner Tacrolimus (FK-506) treatment of fulminant colitis in a child J Pediatr Gastroenterol Nutr 23 1996 329 333
118. MF Neurath R Wanitschke M Peters F Krummenauer KH Meyer zum Buschenfelde JF. Schlaak Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease Gut 44 1999 625 628
119. RL Barnhill NJ Doll LE Millikan RC. Hastings Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes J Am Acad Dermatol 11 1984 814 819
120. KS Bauer SC Dixon WD. Figg Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent Biochem Pharmacol 55 1998 1827 1834
121. ED Ehrenpreis SV Kane LB Cohen SB Hanauer RD. Cohen Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial Gastroenterology 117 1999 1271 1277
122. EA Vasiliauskas LY Kam MT Abreu-Martin PV Hassard KA Papadakis H Yang JB Zeldis SR. Targan An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease Gastroenterology 117 1999 1278 1287
123. Y. Hashimoto Novel biological response modifiers derived from thalidomide Curr Med Chem 5 1998 163 178
124. JB Marriott M Westby S Cookson M Guckian S Goodbourn G Muller MG Shire D Stirling AG. Dagleish CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production J Immunol 161 1998 4236 4243
125. JR Korzenik ME Robert A Bitton M Robinson EJ Scherl RL Fisher HJ. Binder A multi-center, randomized, controlled trial of heparin for the treatment of ulcerative colitis Gastroenterology 116 1999 A752 (abstr)
126. JR. Korzenik IBD: a vascular disorder? The case for heparin therapy Inflamm Bowel Dis 3 1997 87 94
127. RD Pullan J Rhodes S Ganesh V Mani JS Morris GT Williams RG Newcombe MAH Russell C Feyerabend GAO Thomas U. Sawe Transdermal nicotine for active ulcerative colitis N Engl J Med 330 1994 811 815
128. WJ Sandborn WJ Tremaine KP Offord GM Lawson BT Petersen KP Batts IT Croghan LC Dale DR Schroeder RD. Hurt Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial Ann Intern Med 126 1997 364 371
129. GA Thomas J Rhodes K Ragunath V Mani GT Williams RG Newcombe MA Russell C. Feyerabend Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis Eur J Gastroenterol Hepatol 8 1996 769 776
130. RF Compton WJ Sandborn GM Lawson AJ Sheets DC Mays BJ Zins WJ Tremaine JJ Lipsky DW Mahoney AR Zinsmeister KP Offord RD Hurt BK Evans J. Green A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration Aliment Pharmacol Ther 11 1997 865 874
131. JT Green GA Thomas J Rhodes BK Evans MA Russell C Feyerabend GS Fuller RG Newcombe WJ. Sandborn Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis Clin Pharmacol Ther 61 1997 340 348
132. WJ Sandborn WJ Tremaine JA Leighton GM Lawson BJ Zins RF Compton DC Mays JJ Lipsky KP Batts KP Offord RD Hurt J. Green Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study Aliment Pharmacol Ther 11 1997 663 671
133. GS Madretsma GJ Donze AP van Dijk CJ Tak JH Wilson FJ. Zijlstra Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-alpha by human mononuclear cells Immunopharmacology 35 1996 47 51
134. RD. Pullan Colonic mucus, smoking and ulcerative colitis Ann R Coll Surg Engl 78 1996 85 91
135. JM Brandeis MH Sayegh L Gallon RS Blumberg CS. Carpenter Rat intestinal epithelial cells present major histocompatibility complex allopeptides to primed T cells Gastroenterology 107 1994 1537 1542
136. A Tang TA Judge BJ Nickoloff LA. Turka Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand J Immunol 157 1996 117 125
137. JE Buhlmann RJ. Noelle Therapeutic potential for blockade of the CD40 ligand, gp39 J Clin Immunol 16 1996 83 89
138. MF Neurath I Fuss BL Kelsall E Stuber W. Strober Antibodies to interleukin 12 abrogate established experimental colitis in mice J Exp Med 182 1995 1281 1290
139. MF Neurath S Pettersson KH Meyer zum Buschenfelde W. Strober Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice Nat Med 2 1996 998 1004
140. EM Conner SJ Brand JM Davis DY Kang MB. Grisham Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators, and modulators of gene expression Inflamm Bowel Dis 2 1996 133 147
141. S Bjorck A Dahlstrom L Johansson H. Ahlman Treatment of the mucosa with local anaesthetics in ulcerative colitis Agents Actions 1992 Spec No:C60–C72
142. E Arlander A Ost D Stahlberg R. Lofberg Ropivacaine gel in active distal ulcerative colitis and proctitis—a pharmacokinetic and exploratory clinical study Aliment Pharmacol Ther 10 1996 73 81
143. BE. Sands Novel therapies for inflammatory bowel disease Gastroenterol Clin North Am 28 1999 323 351
144. GR Greenberg BG Feagan F Martin LR Sutherland AB Thomson CN Williams LG Nilsson T Persson Canadian Inflammatory Bowel Disease Study Group Oral budesonide for active Crohn’s disease N Engl J Med 331 1994 836 841